R&D channel feed – Endpoints News

R&D channel feed

Amgen spinout Kezar hits PhII hurdle, all eyes on June readout for drug’s other study

4 years ago

Exclusive: Connect Biopharma reports a PhII fail for Zeposia challenger, and execs appear ready to punt

4 years ago

Two struggling biotechs fall under bear market influence, as Spero sharply reduces staff and Sesen seeks sale

4 years ago

Michel Vounatsos is on his way out as Biogen shutters Aduhelm effort and launches pipeline reorg

4 years ago

The R&D challenge: 4 top drug hunters talk best practices in building a biotech today

4 years ago

Stealth's lead drug flunks again, this time in an eye disease, but biotech will attempt to push forward

4 years ago

After culling workforce, migraine biotech Zosano drops lead — and sole — program

4 years ago

Fake news? Narcan maker forced to refute licensing deal after wire service apparently duped by false announcement

4 years ago

Tarsus to raise $75.6M for repurposed dog drug that's headed to FDA after eye drop's PhIII win

4 years ago

Under pressure? FDA pencils in June review dates for Pfizer, Moderna Covid vaccines for kids, plus Novavax EUA

4 years ago

Roche releases more Evrysdi data leading up to FDA decision for very young infants with SMA

4 years ago

FDA tells Praxis it can't move into the clinic just yet for a rare epilepsy drug

4 years ago

Exclusive: Centrexion's knee pain drug fails two PhIII studies, but ex-Pfizer CEO Kindler's biotech might still ask for FDA nod

4 years ago

Bristol Myers celebrates a big win with FDA approval of $13B cardio drug mavacamten

4 years ago

Pfizer can restart PhIII trial of Duchenne gene therapy, now on track for late-2023 FDA approval request

4 years ago

Eli Lilly throws down the gauntlet in obesity race, challenging Novo Nordisk with new PhIII readout

4 years ago

Layoffs hit another biotech as Duchenne player Solid Bio cuts staff by 35%

4 years ago

Covid-19 roundup: Pfizer-BioNTech ask for kid booster EUA; Novartis, Molecular Partners may need another trial for pandemic therapy

4 years ago

Novartis records another tislelizumab win en route to bringing BeiGene's PD-1 to FDA's doors

4 years ago

Scoop: BridgeBio's chief strategy officer resigns as the company quietly embarks on another round of layoffs

4 years ago

Gamida Cell gets IND cleared and clinical hold lifted, paving the way for PhI/II clinical trials

4 years ago

Pfizer and Valneva's Lyme disease bet rolls on to PhIII as more financing flows their way

4 years ago

In wake of IL-2 shutdown, Nektar lets go of 500+ staffers as it promises a turnaround

4 years ago

Protagonist reports a PhII fail in ulcerative colitis, but execs are pushing forward anyway

4 years ago

First page Previous page 137 138 139140141 142 143 Next page Last page